CPC Scientific’s Tirzepatide API Successfully Secures US FDA DMF Filing

CPC Scientific’s Tirzepatide API Successfully Secures US FDA DMF Filing

CPC Scientific, a premier peptide and oligonucleotide-focused CRDMO and a wholly owned subsidiary of Medtide Inc. (HKEX: 3880.HK), today announced that its Hangzhou-based CGMP manufacturing facility, Chinese Peptide Company, has successfully completed the Drug Master File (DMF) filing for its self-developed Tirzepatide active pharmaceutical ingredient (API) with the U.S. Food and Drug Administration (FDA) under DMF number 043979.

Innovative Peptide Manufacturing Methods That Scale

Dive into Joseph Denby's presentation at NextGen Biomed 2026, where he shares a case study on delivering sustainable, efficient peptide manufacturing on scale through our advanced SPPS process optimizations.

DCAT 2026 Highlights: Strengthening Strategic Peptide & Oligo CDMO Partnerships

CPC Scientific had a fantastic time connecting with partners this year at DCAT Week 2026. See our standout highlights from New York, featuring generic API scale-up, the 98th DCAT Annual Dinner, and more...

NextGen Biomed 2026 Highlights: Optimizing Greener TIDES Manufacturing at Scale

Catch CPC Scientific's key highlights from NextGen Biomed 2026, where we showcased how our advanced process design is accelerating production timelines and cost efficiency for greener TIDES manufacturing at scale...

Enabling Sustainable Large-Scale SPPS Through Process Innovations

Delivery of polypeptides in multi-kilogram quantities within commercially competitive timelines is extremely challenging, especially when coupled with a desire to minimize environmental and economic impact. This case study explores how CPC Scientific’s advanced process improvements and efficiencies within solid-phase peptide synthesis (SPPS) have enabled multi-kilogram delivery of a pharmaceutically-relevant decapeptide within a challenging timescale, driving sustainable and cost-saving production for the client.

2025 at a Glance: Celebrating a Year of Peptide & Oligonucleotide CDMO Progress

As 2025 draws to a close, we want to extend our heartfelt thanks to our partners and colleagues around the world! Your trust and collaboration enabled CPC Scientific to make meaningful progress across our CDMO thought leadership, operational scale, and global business milestones this year. Explore featured highlights and resources from the year to see how our people, partners, and platforms drove innovation and impact throughout 2025.

By |December 17th, 2025|Categories: Articles|Tags: |

CPC Scientific Presents Bench-to-Business Playbook at Weill Cornell Graduate School

President Theresa Cheng spoke to PhD students at Weill Cornell Graduate School, sharing industry insights and exploring how academic research today can translate into tomorrow’s cutting-edge healthcare leadership.

By |December 15th, 2025|Categories: Articles, Press Releases|Tags: |

Toward Greener Peptide Manufacturing: Advancing DMF Efficiency in SPPS

Our team has developed an innovative DMF recycling strategy that substantially reduces solvent consumption during solid-phase peptide synthesis. Minimizing use of DMF, a major environmental and cost contributor in peptide manufacturing, has improved process sustainability and cost efficiency. This method neatly demonstrates how targeted green chemistry practices can be successfully integrated into large-scale SPPS, supporting more environmentally responsible and economically viable peptide production.

By |November 28th, 2025|Categories: Green Chemistry, publications, White Papers|Tags: |

Rocklin Facility Construction Update: Advancing U.S.-Based Peptide API Manufacturing

CPC Scientific’s Rocklin facility is undergoing a major expansion to establish a 41,000 sq ft Center of Excellence for U.S.-based peptide API manufacturing. Construction is now underway—more updates coming soon.

How Oligonucleotide CDMOs Drive Innovation & GMP Manufacturing in RNA Therapeutics

From Nusinersen to Inclisiran, oligonucleotide APIs are rapidly reshaping modern drug development. Explore the role of oligonucleotide CDMOs in enabling analytical innovation and scalable, compliant manufacturing across the RNA therapeutic frontier.

Go to Top